



# The 2023 PKU Bio-Net Annual Symposium

October 14<sup>th</sup>, 2023, MIT, Cambridge, MA

08:30 am - 02:00 pm Registration

09:00 am **Opening Remark**

**Xuemei Chen**, University Chair Professor/Dean, School of Life Sciences, Peking University

09:25 am - 12:00 pm **Morning Session**

09:25 am **Keynote Speech**

**Shirley X. Liu**, CEO and co-founder, GV20 Therapeutics

09:50 am **Jian Shu**, Assistant Professor, HMS/MGH/Broad

10:05 am **Xiao Wang**, Assistant Professor, MIT/Broad

10:20 am **Wei Min**, Professor, Columbia

10:35 am Coffee break

10:55 am **Keynote Speech**

**Steve Yuntao Mao**, Editor-in-Chief of Cancer Cell, Publishing Director of CellPress

11:20 am **Panel**

**Panel I: Biomedical Research**

**Chaoran Li**, Assistant Professor, Emory

**Chun Liu**, Assistant Professor, Wisconsin

**Bo Xiao**, Fellow, Broad Institute

**Xin Gu**, Postdoc Research Fellow, HMS/BWH

12:00 pm Photo and Social hours

12:20 pm Lunch

01:30 pm - 05:00 pm **Afternoon Session**

01:30 pm **Keynote Speech**

**Hongkui Deng**, Professor, Director of Stem Cell of Regenerative Medicine, Peking University

01:55 pm **Xu Zhou**, Assistant Professor, HMS/BCH

02:10 pm **Xiaolei Su**, Assistant Professor, Yale

02:25 pm **Tuoqi Wu**, Assistant Professor, UTSW

02:40 pm **Sidi Chen**, Associate Professor, Yale

02:55 pm Coffee break

03:15 pm **Can Cui**, Partner, Goodwin Procter LLP

03:30 pm **Jun Yong**, CEO, GeekGene

03:40 pm **YiZhi Qin**, Cell Sight Revolution

03:50 pm **Ke Xu**, CEO, Meta Pharmaceuticals Inc.

03:55 pm **Dustin Poole**, Director of Sales for the Northeast Region, Novogene Corporation Inc.

04:00 pm **Concurrent Panels**

**Panel II: Biotech Industry**

**Haihui Lu**, Director, Novartis Institutes for BioMedical Research

**Kirsten Zu**, Principal Scientist, Merck

**Hongkang Zhang**, Director, Quiver Bioscience

**Xiao Zang**, Principal Biostatistician, Novartis

**Dustin Poole**, Director of Sales for the Northeast Region, Novogene Corporation Inc.

**Panel III: Beyond Biology**

**Can Cui**, Partner, Goodwin Procter LLP

**Julia Yi Zhu**, Group leader, Insightec

**Yong Dai**, Venture Partner, New Horizon Health Ventures

**Ruth Huan Lai**, Financial Advisor, Portfolio Manager, Merrill Lynch Wealth Management

04:40 pm Snacks, and Teatime

05:00 pm Concluding Remarks

05:10 pm Free style social mixer

Oct. 14<sup>th</sup>, 2023

Massachusetts Institute of Technology  
Boston



GOODWIN



Novogene

Innovent  
信达生物制药



IDG资本  
IDG Capital Partners

MERRILL  
A BANK OF AMERICA COMPANY

诺辉健康  
NEW HORIZON HEALTH

赛得康  
CitoCan



# Innovation Begins Here

No endeavor is too big or small for our Life Sciences practice. Supporting more than 1,700 clients in navigating the unique challenges within the industry, we're with you every step of the way.

Goodwin is a proud sponsor of the 12th annual PKU Bio-Net Symposium. We look forward to the future contributions that PKU's alumni will bring.



See how we help innovators improve lives:  
[goodwinlaw.com/lifesciences](http://goodwinlaw.com/lifesciences)



极客基因是一家以高通量组学数据调控细胞命运为特色的创新型细胞药物开发公司，目前聚焦于制备高质量T细胞治疗中晚期实体瘤。公司成立初期搭建单细胞测序技术相关平台和细胞培养药物筛选平台，并对外提供技术服务。公司拥有世界领先的单细胞多组学数据收集平台、低成本高通量组学技术平台，以及细胞命运重编程技术平台，其核心专利细胞多组学数据收集技术在全球范围内最早获批的专利之一。围绕细胞药这一核心布局积极探索癌症发生发展及免疫细胞作用机理相关前沿问题，极客基因形成了由清华大学、北京大学，解放军第五医学中心，郑大一附院及北京大学肿瘤医院的多位教授及临床专家组成的研究团体。已经开发出针对中晚期实体瘤的细胞治疗产品肿瘤反应T细胞，此款产品含有高比例原初态（naive）属性肿瘤特异T细胞，已经在临床前肿瘤动物模型上获得包括非小细胞肺癌、小细胞肺癌、宫颈癌、膀胱癌、肉瘤等多种实体肿瘤的药效验证数据，目前正在开展临床研究及IND申报。极客基因科技有限公司于2021年3月份获得天使轮融资。2023年1月完成数千万元PreA轮融资，是国家高新技术企业、中关村高新技术企业。2023年2月，在科技部举办的“全国颠覆性技术创新大赛”中，极客基因团队凭借深厚的技术积累和先进的专业理念，荣获最高荣誉优胜奖。



广州超视计生物科技有限公司（超视计科技）是一家专注于**活细胞超分辨成像仪器研发与应用**的高新技术企业。主营业务包括不同类型超分辨光学显微镜的研发、生产、销售、售后及其技术输出服务，服务包括：定制化细胞样本制作服务、定制化细胞样本高通量检测服务、定制化细胞样本成像实验服务、定制化图像后处理和定量分析服务、定制化高维时空数据可视化服务等。

未来，超视计科技将以活细胞智能观测为载体，深耕于高端科研级成像仪器的先进制造、突破革新和应用推广，致力于观测活细胞内的各种微观精细结构及其动态生命过程，结合多组学分析进一步揭示疾病发生发展机制，发现新的疾病生物标志物与创新药物靶

目前公司已获得两轮近亿元融资，投资方均为国内外专注生物医药和医疗器械领域的专业头部机构，强势引导产业端协同赋能。正处于高速发展之中的超视计科技，将以创新作驱动，以技术谋突破，以产品创品牌，为国际领先为使命，继续投身做大做强国产高端智能显微镜行业